PathoQuest signs agreement with MIT to join CAACB as NGS viral safety expert
Paris, France – January 26, 2021 – PathoQuest, a pioneer in quality control testing solutions for biologics using its proprietary next-generation sequencing (NGS) approach, announced today that it has signed an agreement with the Massachusetts Institute of Technology (MIT) to join the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) as an associate member.
PathoQuest brings its 10-year experience in viral safety testing and quality control of biologics to contribute to research programs to help mitigate the risk of adventitious agent contamination in biopharmaceutical manufacturing. This collaboration is expected to translate into practical advances in this field and accelerate the adoption of NGS for the viral safety testing of biologics.
PathoQuest has a long-standing experience in the viral safety testing of biologics. The company has numerous completed and ongoing comparative studies that provide evidentiary support of the robustness of PathoQuest’s proprietary NGS approach to assessing viral safety for vaccines, biotherapeutics, as well as cell and gene therapies.
Dr. Audrey Brussel, Ph.D., PathoQuest’s Viral Safety Leader, will be the company representative to the CAACB in continuation of her previous participation while employed by SANOFI and LFB. Dr. Brussel will provide input based on PathoQuest’s expertise and knowledge associated with the use of NGS as a robust and cost-effective alternative for the viral safety of biologics.
CAACB is an international consortium primarily composed of biopharmaceutical companies that is committed to the exploration and study of approaches to controlling and mitigating the risk of adventitious agent contamination in biomanufacturing. The consortium operates under the auspices of the Massachusetts Institute of Technology’s Center for Biomedical Innovation (MIT-CBI).
“Joining the CAACB is a great opportunity to work closely with key opinion leaders and stakeholders in the field of biopharmaceutical manufacturing, to better understand our clients’ needs and perspective, and as a pioneer of the NGS-approach, to influence efforts to substitute traditional viral safety tests with NGS testing. The CAACB is a driving force in the biomanufacturing industry since it works to address biomanufacturing issues and identify practical solutions for biopharmaceutical manufacturers. PathoQuest will also participate in CAACB projects focused on the use of NGS to replace in vivo quality control testing for biologics”, commented Audrey Brussel, Ph.D., PathoQuest’s Viral Safety Leader
“We are proud to be part of such an influential and expert international consortium that has significant participation from companies within the pharmaceutical biomanufacturing sector. We are confident PathoQuest will make a valuable contribution to this group and help move the industry forward to make bioproduction safer”, stated Jean-François Brepson, PathoQuest’s CEO.
PathoQuest offers biopharmaceutical companies a game-changing genomic approach to ensuring the biosafety of biologics like cell & gene therapy products, vaccines, and recombinant drugs. It also enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences database.
PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
Based on its technological platform, PathoQuest has also developed a metagenomic blood-based test (iDTECT®) designed to improve the diagnosis of bloodstream infections and fight against antimicrobial resistance (AMR).